Introduction {#Sec1}
============

Management of head and neck cancer (HNC) during the COVID-19 outbreak is challenging \[[@CR1]\]. Not only patients diagnosed with HNC are often comorbid and frail \[[@CR2]--[@CR4]\], but may have specific features increasing their risk of being more severely affected by COVID-19 infection \[[@CR5]\]. Treatment-related sequelae, including but not limited to the presence of tracheostomy \[[@CR5]\] and the myelosuppressive action of chemo- and radiotherapy (RT) \[[@CR6]\], further increase the threat of the pandemic on these patients' health. RT represents a mainstay in HNC, both in the definitive and in the post-operative setting \[[@CR7]\]. While the unprecedented COVID-19 emergency is requiring health care professionals to re-define treatment paradigms, there is a general agreement on three basic principles for HNC management in Radiation Oncology: (1) curative-intent RT should be considered as non-deferrable \[[@CR8]\], (2) treatment breaks should be minimized to preserve patients' outcomes \[[@CR9], [@CR10]\], and (3) maintenance of adequate quality standards should be guaranteed, especially when highly conformal techniques are used \[[@CR7], [@CR8]\].

COVID-19 binds to the epithelial cells in the nasal cavities and the oropharynx \[[@CR11]\]. Therefore, as compared with other healthcare professionals, those managing HNC patients are at higher risk of being exposed to aerosolized droplets by asymptomatic carriers \[[@CR12]\]. Therefore, if access to oncological care has to be guaranteed even during the most severe phases of the COVID-19 outbreak, personnel protection needs to be maximized and viral transmission prevented \[[@CR13], [@CR14]\]. As for surgical treatments, patients undergoing RT may be required to remove their medical masks for either physical examination or set-up procedures (e.g. thermoplastic mask positioning), thus requiring additional cautions by healthcare providers. Since swabs-based screenings are hardly extendable to the whole population \[[@CR15]\], it is advisable to consider all patients as COVID-19 asymptomatic carriers and to define adequate personal and environmental protective measurements.

Italy was the first country in Europe hit by the COVID-19 pandemic \[[@CR16]\]. Despite significant differences in contagion rates were found across the country, with Northern regions (namely, Lombardy, Piedmont, Emilia Romagna and Veneto) being the most severely affected areas, all Italian Radiation Oncology facilities were called to respond to the necessity of treating patients at the time of COVID-19 outbreak \[[@CR17]\]. The Italian Association of Radiotherapy and Clinical Oncology (Associazione Italiana di Radioterapia ed Oncologia Clinica, AIRO) has produced a set of general indications and recommendations dedicated to Italian Radiation Oncologists, which are constantly updated and publicly available in Italian and English languages \[[@CR18]--[@CR20]\]. Additionally, dedicated HNC practice recommendations have been recently published thanks to the joint efforts of the American and European Societies of Radiation Oncology (ASTRO and ESTRO, respectively) to optimize indication to treatment of COVID-19 positive HNC patients \[[@CR8]\].

However, recommendations for the re-organization of Radiation Oncology Departments managing HNC are still lacking. With countries such as the USA, Brazil and the Russian Federation still being amid the pandemic peak as of June 22th, there is a persistent need of defining effective and standardized management policies for this subset of patients. Therefore, based on single institutional experiences and on currently available guidelines \[[@CR8], [@CR21]--[@CR23]\], AIRO decided to call national HNC experts to a consensus on practical management of HNC patients facing the COVID-19 pandemic. Aim of the current work was to foster discussion among Italian Fellow Radiation Oncologists, to promote high-quality strategies for HNC and to provide facilities both in the pandemic and in the post-pandemic phase with a practical tool for daily clinical practice.

Methods {#Sec2}
=======

Under endorsement of the AIRO Executive Committee, a panel of 15 Radiation Oncologists with well-recognized expertise in HNC, drafted a preliminary set of items focusing on patients' management and healthcare personnel's protection at the time of the COVID-19 pandemic. Overall, recommendations were tailored on patients without any COVID-19 related symptoms; all patients were therefore considered as potential carriers requiring specific cautions to minimize the risk of cross-infection between patients and health care providers. The whole RT workflow was considered, from first outpatient consultation to follow-up procedures; special attention was given to the sanitization of personal protective equipment (PPE) and sanitization measures of the work environment.

Conversely, Institutional and/or Departmental procedures applied for all oncologic patients (i.e. phone/clinical triage, temperature measurement at the entrance of the hospital) are not discussed in the present consensus as well as in patients' management. Due to time constraints related to the quickly evolving pandemic scenario, a systematic literature review was not performed. Nevertheless, available evidence was considered \[[@CR8], [@CR12], [@CR21], [@CR22]\].

Items were organized into two sections: (1) general recommendations and (2) special recommendations, detailing a set of procedures to be applied to all specific phases of the RT workflow.

On May 10th, 15 Radiation Oncologists with recognized expertise in HNC RT from the major Italian facilities were invited to participate in this project. By May 15th, they had all confirmed their availability. A modified Delphi process was used to grade consensus about each proposed item \[[@CR24]\]. A five-point Likert scale was chosen to grade agreement or disagreement, with possibilities of vote encompassing the following: "strongly agree", "agree", "neutral", "disagree" and "strongly disagree". All votes were given in anonymous form.

The facilitator (DA) circulated the first consensus draft among the participants; modification of original items and/or inclusion of additional topics was allowed in a preliminary round, to meet participants' comments and suggestions. Once items were defined, they were circulated using the online survey tool Google Forms \[[@CR25]\]. Responders had 36 h to complete the first round and 24 h for the second one. In case an item reached the agreement on the first round, it was withdrawn from the second. Conversely, in case consensus failed to reach a 66% threshold, it could be edited according to the panel suggestions, and be re-circulated in the second round.

A cut-off of 75% was set to define "strong agreement", while "agreement" was considered for items reaching at least 66% of consensus among participants \[[@CR24]\].

The final consensus was submitted to 5 senior supervisors (RC, NGDM, SMM, ER, GS), and approved by the AIRO Scientific Committee and Board.

Results {#Sec3}
=======

All invited Radiation Oncologists accepted to participate to the consensus, which reached a 100% response rate in both rounds. The majority of participants (60%) was aged between 40 and 50 years and was equally distributed among genders, with a slight female predominance (60% vs 40%). Seventy-three percent had more than 10 years of experience in HNC management. The distribution of RT facilities across the country was as follows: 47% Northern, 33% Central and 20% Southern Italian regions. Sixty-seven percent of responders were affiliated to University or Research Hospitals, while private and single-specialty centers represented the 13% of the sample. Twenty-seven percent of centers were public hospitals.

The number of items was 55 and 4 in respective rounds. Panelists' responses to each question are detailed in Supplementary Materials.

General recommendations {#Sec4}
-----------------------

Ten items on General Recommendations were structured as following: (1) HNC patients, (2) healthcare professionals, (3) Radiation Oncology Department organization and (4) treatment delivery strategies. All but two items (87%) reached either a strong agreement or agreement during the first round. The two rejected items were re-circulated during the second round, and both failed to achieve a sufficient level of agreement among panelists. Items with the resulting strength of agreement are listed in Table [1](#Tab1){ref-type="table"}.Table 1Strength of Agreement for General Recommendations in HNC Radiation Oncology in the COVID-19 pandemicQuestionStrength of agreement% of agreement^a^Median^b^1. Head and neck cancer patients 1.1. Patients should be required to wear a medical mask to cover their nose and mouth; the medical mask should be maintained during any phase of patient's permanence at the Radiation Oncology Department unless otherwise specified by the healthcare personnelStrong agreement1001 1.2 A second medical mask should be worn in case the patient has a tracheostomy; the second medical mask should be maintained during any phase of patient's permanence at the Radiation Oncology Department unless otherwise specified by the healthcare personnelStrong agreement93.31 1.3 Hand sanitization (by either direct hand sanitization with hydroalcoholic-based disinfectants or by the use of gloves) should be performed, and repeated before each procedureStrong agreement1001 1.4 Any swallowing and/or respiratory impairment which could exacerbate cough and mucous secretion should be minimized whenever possibleStrong agreement93.31 1.5 Any swallowing and/or respiratory impairment which could increase the risk of ab-ingestis pneumonitis should be minimized whenever possibleStrong agreement93.312. Health care professionals 2.1 Any medical and technical procedures requiring the patient to remove his/her medical mask should be considered at high risk of viral disseminationStrong agreement86.71 2.2 Health care professionals (Medical Doctors, Radiation Therapists and Nurses) involved in the management of HNC patients should wear gloves, goggles (or, alternatively, a face shield), gowns, respirators (i.e., N95 or FFP2 standard or equivalent) and aprons in any phase of the RT courseAgreement66.7Equal3. Radiation oncology department organization 3.1 At least one consultation room should be dedicated to weekly HNC patients examinations during RT delivery for radiation-related acute toxicities (in case medical mask removal is required)^c^No agreement60-- 3.2 At least one consultation room should be dedicated for HNC patients nursing care (i.e. skin medications, in case medical mask removal is required)Agreement73.32 3.3 Extra sanitization procedures according to Institutional policies should be applied for rooms dedicated to HNC patients^c^No agreement60--*FFP2* class II filtering facepiece, *HNC* head and neck cancer, *RT* radiotherapy^a^% of agreement is computed as the sum of responses "strongly agree" and "agree"^b^Median can be either 1, if "strongly agree" answers prevailed, 2, if "agree" answers prevailed or "equal" if neither prevailed^c^These questions were proposed again in the second round but agreement was not reached

Special recommendations {#Sec5}
-----------------------

Forty-five items were categorized as special recommendations, and were organized as following: (1) indication to treatment, (2) first outpatient consultation, (3) computed tomography (CT) simulation procedure, (4) treatment delivery strategy, (5) RT treatment sessions (6) in-treatment consultations, (7) patients with suspected COVID-19 infection, and (8) follow-up consultations.

Of these, 36/40 (90%) reached the consensus at the end of the first round. Two items were re-circulated during the second round: one was slightly edited following the panel's requirement (item 5.3, "Indication to treatment": an example of alternative treatment strategy for early-stage HNC was provided), and was approved during the second round with a strong level of agreement. Another item (6.5, "First Outpatient Consultation") reached the agreement during the second round.

Two items were withdrawn from the second round by the facilitator to meet panelists' observations. Specifically, one item, included among the "Computer tomography (CT) simulation procedures", considered the possibility of positioning the medical masks over the thermoplastic mask in case it was not possible for the patient to wear it under the immobilization device. More than one quarter of the responders disagreed with the statement, while one third rated it as "neutral". As no suggestions nor comments were provided for item modification, it was not admitted to the second round. The second excluded statement (originally included among the "Patients with suspected COVID-19 infection" sub-section) was formulated as following: "In case of treatment interruption for COVID-19 infection, at least two negative nasal and oropharyngeal swab tests are required before the patient can be re-admitted to the hospital". Despite the statement mirrored local health policies, it was judged both as hardly generalizable and not in line with existing recommendations \[[@CR8]\], and was therefore removed after the first round.

Items at the end of the two rounds are collected in Table [2](#Tab2){ref-type="table"} with the corresponding level of agreement.Table 2Strength of agreement for special recommendations in HNC Radiation Oncology in the COVID-19 pandemicQuestionStrength of agreement% of agreement^a^Median^b^5. Indication to treatment 5.1 Multidisciplinary team meetings should be maintained in compliance of social distancing rules or via tele-meetingsStrong agreement1001 5.2 Treatment indications should comply with the recently published ASTRO/ESTRO practice recommendationsStrong agreement80Equal 5.3 Alternative treatment strategies should be considered for early-stage HN tumors (i.e. endoscopic surgery for early glottis tumors)Strong agreement^c^86.72 5.4 Indication to palliative treatments should be weighed against the increased risk of viral exposure in the hospital environmentStrong agreement80Equal6. First outpatient consultation 6.1 A phone triage should be performed before patients are admitted in the HospitalStrong agreement86.71 6.2 Clinical history on COVID-19 related symptoms should be collectedStrong agreement93.31 6.3 Close contact with COVID-19 positive cases should be collectedStrong agreement93.31 6.4 In case of suspected COVID-19 infection, patients should be tested (with nasal/oropharyngeal swabs preceding clinical examination)Strong agreement93.31 6.5 Patients who are not resident in the same region as the treating facility should be invited to seek for a Radiation Oncology consultation and to perform RT close to their domicileAgreement^d^66.7Equal 6.6 At least medical beds and room equipment should be cleaned with hydroalcoholic disinfectants after each useStrong agreement86.71 6.7 Extra sanitization procedures according to Institutional policies should be applied for examination rooms dedicated to HNC patientsAgreement66.72 6.8 During the clinical examination, any accompanying person should be invited to wait outside the DepartmentStrong agreement86.727. CT simulation procedures 7.1 Clinical history on COVID-19 related symptoms should be collected before the CT simulation procedureStrong agreement86.71 7.2 Close interaction with COVID-19 positive contacts should be collected before the CT simulation procedureStrong agreement801 7.3 In case patients need to remove his/her medical mask, health care professionals should be considered at high risk for COVID-19 infection and equipped accordinglyStrong agreement802 7.4 Thermoplastic masks as well as all set-up devices should be cleaned with hydroalcoholic-based disinfectants after each procedureStrong agreement93.31 7.5 Set-up devices should be used according to the RT technique of choice, and according to standard Departmental proceduresStrong agreement1001 7.6 If patients need to remove his/her medical mask, the simulation CT room should be cleaned in compliance with a structured sanitation protocolStrong agreement801 7.7 CT simulation scheduling should be arranged to allow adequate room sanitization according to Institutional policiesStrong agreement802 7.8 Should it be unfeasible for the patient to wear his/her medical mask under the thermoplastic mask, an attempt should be made to position the surgical mask above the thermoplastic maskNo agreement40-- 7.9 After each procedure, health care professionals have to remove gloves, wash their hands accurately, sanitize their goggles (or face shields) with hydroalcoholic solutionStrong agreement93.31 7.10 All thermoplastic masks and individual set-up devices should be stored in protective disposable bagsStrong agreement8018. Treatment delivery strategy 8.1 Treatment planning strategies (i.e. treatment technique) should be maintained according to Departmental standard of careStrong agreement1001 8.2 In case any modification of set-up is required (i.e. cutting the thermoplastic mask to improve patients' tolerance to RT, if needed), the possibility of higher uncertainties in patient's positioning should be considered and managed as neededStrong agreement1001 8.3 In case of any modification of the thermoplastic mask, it is advised to maintain a strong fixation of at least the patient's chin and noseStrong agreement1001 8.4 In case any significant modification of set-up devices (i.e. omission of tools such as the mouth-piece bite), the subsequent CTV-PTV margins should be modified to account for set-up uncertaintiesStrong agreement86.71 8.5 In case of any modification of the thermoplastic mask it is recommended to applied more strict set-up protocols (i.e. daily image guided radiotherapy)Strong agreement86.719. RT treatment sessions 9.1 Patients should not be accompanied in the Radiation Oncology waiting room, unless strictly necessary (i.e. language barriers)Strong agreement93.31 9.2 In case several patients are in the same waiting room, adequate social distancing procedures should be respectedStrong agreement1001 9.3 In case patients need to remove his/her medical mask, health care professionals should be considered at high risk for COVID-19 infection and equipped accordinglyStrong agreement86.72 9.4 Thermoplastic masks as well as all set-up devices should be cleaned with hydro alcoholic-based disinfectants after each procedureStrong agreement93.31 9.5 All thermoplastic masks and individual set-up devices should be stored in protective disposable bagsAgreement73.3110. In-treatment consultations 10.1 Acute RT-related toxicity should be treated according to the Departmental standard of careStrong agreement1001 10.2 Patients should be examined at least once per week for RT-related acute toxicity assessmentStrong agreement93.31 10.3 Clinical history on COVID-19 related symptoms should be collected during each consultationStrong agreement1001 10.4 Close interaction with COVID-19 positive contacts should be collected during each consultationStrong agreement86.71 10.5 Patients should be trained to perform basic skin medications on their own to minimize medical mask removal during the course of treatmentStrong agreement86.72 10.6 Both the consultation room(s) and the Infirmary should be sanitized according to Institutional policiesStrong agreement80111. Suspected COVID-19 infection 11.1 In case of suspected COVID-19 infection, patients should be tested by nasal and oropharyngeal swab testStrong agreement93.31 11.2 In case of COVID-19 infection, clinicians are invited to comply with ASTRO/ESTRO practice recommendationsStrong agreement93.3Equal 11.3 In case of treatment interruption for COVID-19 infection, at least two negative nasal and oropharyngeal swab tests are required before the patient can be re-admitted to the HospitalNo agreement60-- 11.4 In case of prolonged treatment interruptions for severe COVID-19 infection, a multidisciplinary discussion should either confirm or re-define the patient's programStrong agreement100112. Follow-up consultations 12.1 For patients at low risk of loco-regional recurrence and without relevant symptoms, telehealth surveillance should be performed via phone calls to assess clinical status and results of prescribed radiological examinationsStrong agreement93.31 12.2 Face-to-Face consultations should be maintained in case of either (1) need for clinical evaluation of tumor response to treatment, (2) high-risk of local recurrence, (3) patients with reporting any cancer-related symptoms and/or signsStrong agreement1001 12.3 During the follow up consultations, the above-mentioned recommendations for the first outpatient consultations should be respectedStrong agreement1001*ASTRO* American Society for Radiation Oncology, *CT* computed tomography, *CTV* clinical target volume, *ESTRO* European Society for Radiotherapy and Oncology, *HN* head and neck, *HNC* HN cancer, *PTV* planning target volume, *RT* radiotherapy^a^% of agreement is computed as the sum of responses "strongly agree" and "agree"^b^Median can be either 1, if "strongly agree" answers prevailed, 2, if "agree" answers prevailed or "equal" if neither prevailed^c^Modified between 1st and 2nd round to address some comments from responders. Strong agreement reached after 2nd round^d^Agreement was reached after 2nd round

Discussion {#Sec6}
==========

The aim of these practice recommendations by the AIRO was to provide a decisional framework for Radiation Oncologists treating HNC patients at the time of the COVID-19 pandemic. While in Italy the lockdown is progressively being mitigated for the general population, hospitals remain at high risk of cross-contamination for patients and healthcare professionals \[[@CR12], [@CR26], [@CR27]\]. With a number of COVID-19-positive cases in Italy of 230.000 cases as of May 25th 2020 and a potentially higher number of undiagnosed asymptomatic carriers, it is critical to maintain the highest quality of safety procedures when treating HNC malignancies. With this awareness, we propose this set of recommendations for every-day clinical workflow.

Relevant phases of Radiation Oncology workflow were reviewed, discussed and optimized in the light of the Italian experience of the last 3 months.

Given the different distribution of COVID-19 incidence and prevalence across the country, the panel was required to evaluate the issue of patients' relocation in another region for RT delivery. While responders generally agreed on the possibility of recommending treating facilities close to the patient's domicile, a strong degree of consensus was not reached. Specifically, responders suggested considering high-volume centers whenever possible, as both RT technique and treating Radiation Oncologist's experience have been associated with better oncological outcomes \[[@CR28]\].

Overall, the panel underlined that multidisciplinary team meetings should be maintained to discuss individual indication to RT. As the issue of locally-advanced disease had already been analyzed \[[@CR29]\], it was not proposed to the current panel. Conversely, the possibility of offering alternative treatment strategies was discussed and approved for early-stage tumors, such as mini-invasive surgery for T1--T2 cancers of the glottis. Indeed, although hypofractionated schemes may be proposed, 20 is the lowest currently accepted number of fractions for curative-intent treatments \[[@CR8]\]. Therefore, the choice to address to mini-invasive surgery would have the advantage to prevent patients from multiple accesses to the hospital and therefore limit the risk of cross-contamination. Considering the palliative setting \[[@CR8]\], the prescription of extreme hypofractionation (even in a single fraction of 8 Gy) could optimize the ratio between the risk of infection and the expected benefits of irradiation.

Agreement was found on patients' clinical management from the first outpatient consultation by the Radiation Oncologist to follow-up scheduling. Some observations by the responders focused on the presence of accompanying persons during the RT workflow. Respecting social distancing measures was recognized as a priority in all environments. To this aim, caregivers' access to the Radiation Oncology Department should be discouraged. However, the panel recognized that a caregiver could attend medical consultations in selected cases (i.e. senior individuals, speech impairment, and linguistic barriers). As the reduction of psychological distress has been correlated with increased compliance to treatment and better oncological outcomes \[[@CR30]\], caution in balancing strict safety policies and support from the caregivers is advised for this subset of patients.

While Italian practical recommendations on general re-organization policies of Radiation Oncology Departments have been already provided \[[@CR20]\], we focused on additional issues specific to HNC care. Continuity of care was considered as a priority, with all experts recommending maintaining at least a weekly clinical examination for the assessment of RT-related acute toxicity. The panel recognized the importance of patients' compliance in observing general protection measurements \[[@CR12]\]. Agreement, although with lesser strength (66.7%), was reached on healthcare professionals protections. This might be due to different local policies on the use of PPE \[[@CR17]\].

Allocation of consultation rooms was also debated: while the panel strongly agreed on reserving a room for nursing care (i.e. skin medications, in case medical masks removal is required), the allocation of a dedicated consultation room was not considered as relevant. Moreover, some panelist highlighted that nursing care of minor events (i.e. low-grade skin toxicity and mucositis) could be maintained in case expertise in HNC is already available.

General sanitization measurements have been diffusely implemented in Radiation Oncology facilities to decrease COVID-19 cross-infection \[[@CR31]\]. Of note, HNC patients require a more frequent removal of their medical mask than other patients: the need of performing clinical examinations (i.e. oral cavity inspection, fibroscopy) exposes to a higher risk of environmental and personnel's contamination, together with the presence of cough and/or mucous secretions. As a consequence, the panel underlines the need of accurate disinfection of surfaces (i.e. room equipment, medical instrumentation) and RT set-up devices. Conversely, an agreement was not reached for extra-sanitization procedures (i.e. sanitization of medical rooms dedicated to HNC patients at the each working day). Admittedly, there is no current evidence that such procedures might be effective in further reducing the risk of cross-contamination when treating patients without COVID-19 relatable symptoms.

The panel showed a high consensus agreement when addressing items on set-up modifications: even in the midst of the COVID-19 emergency, priority should be maintained in avoiding any uncertainty in either treatment planning or delivery. Therefore, in case of modifications in immobilization devices (i.e. cutting of the thermoplastic mask), dedicated measurements should be applied, especially when high-conformal techniques with steep dose gradients are used \[[@CR32], [@CR33]\].

While the panel jointly considered first Radiation Oncology consultations as non-deferrable, distinctions are to be considered follow-up examinations. As intensive follow-up has not been associated with significant improvements in HNC patients' oncological outcomes \[[@CR34]\], most of the responders agreed on re-scheduling follow-up consultations in those who are asymptomatic and/or at low-risk of local recurrence. Conversely, our recommendation is to maintain scheduled appointments in all other clinical scenarios, and whenever a direct assessment of clinical response to curative-intent RT is needed.

The recently published ASTRO/ESTRO practice guidelines \[[@CR8]\] recommend to prioritize RT delivery in swab-proven COVID-19 positive patients in case of mild symptomatic presentation who had already completed the first two weeks of treatment. Generally, the AIRO panelists agreed to comply with the above-described recommendations. However, no agreement was reached on the need of having two consecutive negative swab tests for re-admittance to RT. Heterogeneity was also found in indications to re-start RT among different centers who participated to the ASTRO/ESTRO consensus. Therefore, given the rarity of HNCs \[[@CR35]\] and the above-detailed peculiarities of its management, the panel advices to perform systematic swabs test upon first patients' admittance in Radiation Oncology Department. This would allow to anticipate the diagnosis of COVID-19 positive cases to consider tailored treatment strategies.

Although we strongly believe in the value of consensus-based practice recommendations, some limitations should be considered. Firstly, if resources and working organization are not homogenous among treatment facilities, discrepancies among centers may be intensified in times of limited resources. Overall, it is not possible to make reliable predictions on the outbreak duration and severity, regardless of the pandemic phase. Consequently, clinicians may be forced to disregard our practice recommendations, despite the strong level of agreement we could reach for most of them. Flexibility and physicians' judgment should therefore be the guidance in finding the optimal balance between available resources and the best clinical practice at the safest conditions for healthcare providers.

Since Italy has been one the first and most severely affected countries, we hope that our hands-on consensus could be of value for other Fellow Colleagues still facing the COVID-19 outbreak while this manuscript is being written. As the epidemiological scenario is gradually improving in our country, novel regulations are currently under evaluation to adapt individual and institutional behaviors. We believe that our recommendations could also provide an easily adaptable tool for the upcoming post-pandemic phase, and meet the evolving needs of Radiation Oncologists treating HNC patients.

Conclusion {#Sec7}
==========

Based on the joint experience of the Italian Head and Neck Radiation Oncology community, this work provides a comprehensive set of clinical practice recommendations to be implemented in every phase of the RT workflow during the COVID-19 pandemic.
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